

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

1.(currently amended) A method of mitigating the adverse effects of antiviral agents in HIV therapy comprising ~~(1)~~-administering to an HIV-infected subject at least one antiviral agent until HIV is suppressed, ~~(2)~~-discontinuing antiviral therapy, ~~(3)~~ administering a dsRNA, then, when HIV values increase ~~(4)~~-resuming antiviral treatment with the at least one antiviral agent.

2.(currently amended) he method of claim 1 wherein step ~~(1)~~-a dsRNA is administered with said antiviral agent.

3.(currently amended) The method of claim 1 ~~or 2~~-wherein step ~~(1)~~-HIV values are suppressed to a value below detection.

4.(original) The method of claim 3 wherein the value is less than 50 copies/ml of HIV plasma RNA.

5.(currently amended) The claim 1 ~~or 2~~-wherein two or more anti-retroviral agents are used.

6.(original) The method of claim 5 wherein the anti-retroviral drug is selected from abacavir, amprenavir, zidovudine, combivir, zalcitabine, lamivudine, didanosine, trizivir, stavudine, lopinavir, efavirenz, nevirapine, indinavir, delavirdine, ritonavir, saquinavir, nelfinvir and tenofovir.

CARTER, W. et al.

Appl. No. To be assigned

US National Phase of PCT/US02/39890

June 14, 2004

7.(currently amended) The method of claim 1-~~or~~2 where the dsRNA is rI_n
 $r(C_{12}U)_n$, Poly A Poly U or $rI_n r(C_{29},G)_n$, in which r is ribo and n has a value of 4 to 29.